Hexima Limited (HXL) is a clinical-stage biotechnology company specialising in anti-infectives. The company is focused on researching and developing plant defensin peptides for use as human therapeutics. Hexima is advancing pezadeftide, which is being developed as a potentially safe, convenient, and effective topical prescription treatment for fungal nail infections (onychomycosis).